Quarterly report · Q3
2784.TEDINET S100SVSS
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.18T | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥2.70T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.05T | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥29.9bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥20.0bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥31.2bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥32.8bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥22.0bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥30.9bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥22.7bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥20.9bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥25.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥14.8bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥20.9bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥14.9bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥1.50T | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥1.34T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.44T | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.04T | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥851.5bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥464.3bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥488.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥481.9bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥200.8bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥160.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥107.92 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.22 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥127.42 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥73.24 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.64 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 30.9% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.4% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.5% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 45
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥26.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥26.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | ¥290m |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥1.94T |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥1.92T |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥14.0bn |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥25.9bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥40.0bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥28.2bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥11.7bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥1.1bn |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥27.5bn |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥27.5bn |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥484m |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥200.4bn |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥200.0bn |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥395m |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥2.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-12-31 | ¥2.21T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-12-31 | ¥2.18T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥26.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-12-31 | ¥29.7bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥24.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥24.1bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | ¥372m |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥1.82T |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥1.81T |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥13.1bn |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥16.9bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥36.4bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥25.8bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥10.6bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥992m |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥27.1bn |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥27.1bn |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥0 |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥43m |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥186.8bn |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥186.3bn |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥429m |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥2.07T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥2.05T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥24.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥19.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 381
| Item | Context | Value | Unit |
|---|---|---|---|
| Company name cover page | FilingDateInstant | Original text (Japanese)アルフレッサ ホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | Alfresa Holdings Corporation | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 荒川 隆治 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都千代田区大手町一丁目１番３号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-5219-5100 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)代表取締役 副社長社長補佐 総務・財務企画・コーポレートコミュニケーション・コンプライアンス担当岸田 誠一 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都千代田区大手町一丁目１番３号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-5219-5100 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)代表取締役 副社長社長補佐 総務・財務企画・コーポレートコミュニケーション・コンプライアンス担当岸田 誠一 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E02962 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 27840 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)アルフレッサ ホールディングス株式会社 | |
| Filer name in english | FilingDateInstant | Alfresa Holdings Corporation | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Current period end date | FilingDateInstant | 2023-12-31 | |
| Type of current period | FilingDateInstant | Q3 | |
| Current fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Comparative period end date | FilingDateInstant | 2022-12-31 | |
| Previous fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数 100株 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |